Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Berkowitz

Adult Reconstructive Orthopaedic Surgery Tamarac, FL Medical Doctor

NPI 1811994544 CMS profile 386401

7171 N University Dr, Suite 100, Tamarac, FL 33321

Open in the dashboard

General payments

$49,641

105 records reported · program years 2019–2025

Research payments

$8,797

Paid to them · 23 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,744,981 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Richard Berkowitz of Tamarac, FL is reported in the CMS Open Payments database as having received $49,641 across 105 general payments and $8,797 in research payments paid to them. Separately, studies naming them as principal investigator received $1,744,981 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $407 4
2025 Research $8,797 23
2024 General $31,319 30
2023 General $203 3
2022 General $1,729 19
2021 General $1,216 11
2020 General $153 6
2019 General $14,614 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Berkowitz
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Richard Berkowitz were reported at $407. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Richard Berkowitz Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $14,614 $1,416 $292–$9,336 $163
2020 $153 $647 $141–$6,474 $114
2021 $1,216 $1,073 $211–$6,497 $132
2022 $1,729 $1,217 $236–$6,299 $149
2023 $203 $1,082 $246–$6,818 $160
2024 $31,319 $1,575 $323–$8,944 $164
2025 $407 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $20,570 36 payments
  2. Vertex Pharmaceuticals Incorporated $12,034 10 payments
  3. Janssen Research & Development, LLC $10,130 5 payments
  4. Heron Therapeutics, Inc. $4,153 19 payments
  5. Globus Medical, Inc. $1,013 6 payments
  6. Baudax Bio Inc. $850 1 payment
  7. Zimmer Biomet Holdings, Inc. $386 9 payments
  8. Intuitive Surgical, Inc. $164 6 payments
  9. AcelRx Pharmaceuticals, Inc. $88 1 payment
  10. Flexion Therapeutics, Inc. $64 3 payments
  11. Other $188 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $25,890 3 payments
  2. Travel and Lodging $19,342 29 payments
  3. Food and Beverage $3,558 72 payments
  4. Honoraria $850 1 payment
Products named General payments · program years 2019–2025
  1. HTX-011 $4,108 17 payments
  2. EZOUT $1,816 4 payments
  3. ANJESO $850 1 payment
  4. Joint Reconstruction $484 1 payment
  5. ORTHOMAP $356 3 payments
  6. ACCOLADE $341 3 payments
  7. TRIATHLON $266 4 payments
  8. MAKO $218 4 payments
  9. SECUR-FIT $191 3 payments
  10. ROSA $178 5 payments
  11. Other $2,075 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $8,797 23 payments

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,097

Median for Orthopedic Surgery: 203

Drug cost

$55,891

Median for Orthopedic Surgery: $1,433

Branded share of claims

44.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 89 $47,084
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 368 $3,717
Cephalexin Generic 274 $2,787
Celecoxib Generic 41 $627
Methylprednisolone Acetate Generic 16 $464
Tramadol Hcl Generic 203 $452
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $323
Clindamycin Hcl Generic 34 $247
Diclofenac Sodium Generic 13 $104
Ondansetron Hcl Generic 12 $62

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$110,600

Of which drugs: $6,367

Medicare patients

207

Average age 76

Services billed

1,968

134 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Ischemic heart disease 37%
Chronic kidney disease 35%
Depression 35%
Atrial fibrillation 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 14 544 $3,753
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 75 409 $2,238

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record